A citation-based method for searching scientific literature

K N Gaarenstroom, B van der Hiel, R A E M Tollenaar, G R Vink, F W Jansen, C J van Asperen, G G Kenter. Int J Gynecol Cancer 2006
Times Cited: 39







List of co-cited articles
362 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Timothy R Rebbeck, Henry T Lynch, Susan L Neuhausen, Steven A Narod, Laura Van't Veer, Judy E Garber, Gareth Evans, Claudine Isaacs, Mary B Daly, Ellen Matloff,[...]. N Engl J Med 2002
48

Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.
Diane Stirling, D Gareth R Evans, Gabriella Pichert, Andrew Shenton, Elaine N Kirk, Sylvia Rimmer, C Michael Steel, Sheila Lawson, R M Camille Busby-Earle, Jane Walker,[...]. J Clin Oncol 2005
110
46

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D Kauff, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat,[...]. N Engl J Med 2002
868
43

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
38

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Amy Finch, Mario Beiner, Jan Lubinski, Henry T Lynch, Pal Moller, Barry Rosen, Joan Murphy, Parviz Ghadirian, Eitan Friedman, William D Foulkes,[...]. JAMA 2006
394
38

Surveillance of women at high risk for hereditary ovarian cancer is inefficient.
A L Oei, L F Massuger, J Bulten, M J Ligtenberg, N Hoogerbrugge, J A de Hullu. Br J Cancer 2006
58
33

Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Lauren Scheuer, Noah Kauff, Mark Robson, Bridget Kelly, Richard Barakat, Jaya Satagopan, Nathan Ellis, Martee Hensley, Jeff Boyd, Patrick Borgen,[...]. J Clin Oncol 2002
307
33

Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
Paul A M Meeuwissen, Caroline Seynaeve, Cecile T M Brekelmans, Hanne J Meijers-Heijboer, Jan G M Klijn, Curt W Burger. Gynecol Oncol 2005
68
30


No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
B B J Hermsen, R I Olivier, R H M Verheijen, M van Beurden, J A de Hullu, L F Massuger, C W Burger, C T Brekelmans, M J Mourits, G H de Bock,[...]. Br J Cancer 2007
97
30

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Usha Menon, Aleksandra Gentry-Maharaj, Rachel Hallett, Andy Ryan, Matthew Burnell, Aarti Sharma, Sara Lewis, Susan Davies, Susan Philpott, Alberto Lopes,[...]. Lancet Oncol 2009
503
28

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
25


Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Theresa Wagner, Henry T Lynch, Judy E Garber, Mary B Daly, Claudine Isaacs, Olufunmilayo I Olopade, Susan L Neuhausen, Laura van 't Veer,[...]. J Clin Oncol 2005
268
23

Early detection of breast and ovarian cancer in families with BRCA mutations.
H F A Vasen, E Tesfay, H Boonstra, M J E Mourits, E Rutgers, R Verheyen, J Oosterwijk, L Beex. Eur J Cancer 2005
52
23

Cancer risk in mutation carriers of DNA-mismatch-repair genes.
M Aarnio, R Sankila, E Pukkala, R Salovaara, L A Aaltonen, A de la Chapelle, P Peltomäki, J P Mecklin, H J Järvinen. Int J Cancer 1999
812
23

Improved survival in women with BRCA-associated ovarian carcinoma.
Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A Narod, Beth Y Karlan. Cancer 2003
340
23

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
Nienke M van der Velde, Marian J E Mourits, Henriëtte J G Arts, Jacob de Vries, Beike K Leegte, Grieteke Dijkhuis, Jan C Oosterwijk, Geertruida H de Bock. Int J Cancer 2009
83
23

Use of CA-125 and ultrasound in high-risk women.
Stéphane Laframboise, R Nedelcu, J Murphy, D E C Cole, B Rosen. Int J Gynecol Cancer 2002
29
27

Screening for ovarian cancer: a pilot randomised controlled trial.
I J Jacobs, S J Skates, N MacDonald, U Menon, A N Rosenthal, A P Davies, R Woolas, A R Jeyarajah, K Sibley, D G Lowe,[...]. Lancet 1999
371
20

Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
Kathleen M Schmeler, Henry T Lynch, Lee-may Chen, Mark F Munsell, Pamela T Soliman, Mary Beth Clark, Molly S Daniels, Kristin G White, Stephanie G Boyd-Rogers, Peggy G Conrad,[...]. N Engl J Med 2006
472
20

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
C Bethan Powell, Eric Kenley, Lee-May Chen, Beth Crawford, Jane McLennan, Charles Zaloudek, Miriam Komaromy, Mary Beattie, John Ziegler. J Clin Oncol 2005
253
20

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.
Fabiola Medeiros, Michael G Muto, Yonghee Lee, Julia A Elvin, Michael J Callahan, Colleen Feltmate, Judy E Garber, Daniel W Cramer, Christopher P Crum. Am J Surg Pathol 2006
561
20

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
20

Prospectively detected cancer in familial breast/ovarian cancer screening.
A Dørum, K Heimdal, K Løvslett, G Kristensen, L J Hansen, R Sandvei, A Schiefloe, B Hagen, A Himmelmann, F Jerve,[...]. Acta Obstet Gynecol Scand 1999
35
22

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Noah D Kauff, Susan M Domchek, Tara M Friebel, Mark E Robson, Johanna Lee, Judy E Garber, Claudine Isaacs, D Gareth Evans, Henry Lynch, Rosalind A Eeles,[...]. J Clin Oncol 2008
359
20

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Saundra S Buys, Edward Partridge, Amanda Black, Christine C Johnson, Lois Lamerato, Claudine Isaacs, Douglas J Reding, Robert T Greenlee, Lance A Yokochi, Bruce Kessel,[...]. JAMA 2011
731
20

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations.
A S Whittemore, R R Balise, P D P Pharoah, R A Dicioccio, I Oakley-Girvan, S J Ramus, M Daly, M B Usinowicz, K Garlinghouse-Jones, B A J Ponder,[...]. Br J Cancer 2004
82
17

Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
A Tailor, T H Bourne, S Campbell, E Okokon, T Dew, W P Collins. Ultrasound Obstet Gynecol 2003
31
22

Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Susan M Domchek, Tara M Friebel, Susan L Neuhausen, Theresa Wagner, Gareth Evans, Claudine Isaacs, Judy E Garber, Mary B Daly, Rosalind Eeles, Ellen Matloff,[...]. Lancet Oncol 2006
211
17

Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Alexander Liede, Beth Y Karlan, Rae Lynn Baldwin, Lawrence D Platt, Graciela Kuperstein, Steven A Narod. J Clin Oncol 2002
66
15

Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
Douglas A Levine, Peter A Argenta, Cindy J Yee, David S Marshall, Narciso Olvera, Faina Bogomolniy, Jamal A Rahaman, Mark E Robson, Kenneth Offit, Richard R Barakat,[...]. J Clin Oncol 2003
120
15

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Steven A Narod, Marie-Pierre Dubé, Jan Klijn, Jan Lubinski, Henry T Lynch, Parviz Ghadirian, Diane Provencher, Ketil Heimdal, Pal Moller, Mark Robson,[...]. J Natl Cancer Inst 2002
221
15


Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
John R McLaughlin, Harvey A Risch, Jan Lubinski, Pal Moller, Parviz Ghadirian, Henry Lynch, Beth Karlan, David Fishman, Barry Rosen, Susan L Neuhausen,[...]. Lancet Oncol 2007
140
15

Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
S A Narod, H Risch, R Moslehi, A Dørum, S Neuhausen, H Olsson, D Provencher, P Radice, G Evans, S Bishop,[...]. N Engl J Med 1998
384
15

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Joanna B Madalinska, Judith Hollenstein, Eveline Bleiker, Marc van Beurden, Heiddis B Valdimarsdottir, Leon F Massuger, Katja N Gaarenstroom, Marian J E Mourits, René H M Verheijen, Eleonora B L van Dorst,[...]. J Clin Oncol 2005
167
15


Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened.
John R van Nagell, Paul D DePriest, Frederick R Ueland, Christopher P DeSimone, Amy L Cooper, J Matt McDonald, Edward J Pavlik, Richard J Kryscio. Cancer 2007
131
15

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
15

Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
Michael J Callahan, Christopher P Crum, Fabiola Medeiros, David W Kindelberger, Julia A Elvin, Judy E Garber, Colleen M Feltmate, Ross S Berkowitz, Michael G Muto. J Clin Oncol 2007
336
15

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Tuya Pal, Jenny Permuth-Wey, Judith A Betts, Jeffrey P Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A Martino, Katie Wakeley,[...]. Cancer 2005
505
15

Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective.
E R Woodward, H V Sleightholme, A M Considine, S Williamson, J M McHugo, D G Cruger. BJOG 2007
63
15

Serum protein markers for early detection of ovarian cancer.
Gil Mor, Irene Visintin, Yinglei Lai, Hongyu Zhao, Peter Schwartz, Thomas Rutherford, Luo Yue, Patricia Bray-Ward, David C Ward. Proc Natl Acad Sci U S A 2005
320
12



Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
J Boyd, Y Sonoda, M G Federici, F Bogomolniy, E Rhei, D L Maresco, P E Saigo, L A Almadrones, R R Barakat, C L Brown,[...]. JAMA 2000
380
12

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
H A Risch, J R McLaughlin, D E Cole, B Rosen, L Bradley, E Kwan, E Jack, D J Vesprini, G Kuperstein, J L Abrahamson,[...]. Am J Hum Genet 2001
718
12

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
J P Struewing, P Hartge, S Wacholder, S M Baker, M Berlin, M McAdams, M M Timmerman, L C Brody, M A Tucker. N Engl J Med 1997
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.